News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Neil Bhowmick, PhD

Articles by Neil Bhowmick, PhD

Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification

ByBethany Smith, PhD,Sungjin Kim, MS ,Mourad Tighiouart, PhD,Edwin M. Posadas, MD,Leland Chung, PhD,Robert A. Figlin, MD,Neil Bhowmick, PhD,Jun Gong, MD

September 14th 2021

This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.

Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics

ByJun Gong, MD,Edwin M. Posadas, MD,Neil Bhowmick, PhD,Hyung L. Kim, MD,Timothy J. Daskivich, MD,Amit Gupta, MD,Howard M. Sandler, MD,Mitchell Kamrava, MD,Zachary S. Zumsteg, MD,Stephen J. Freedland, MD,Robert A. Figlin, MD

March 17th 2021

Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.

Latest Updated Articles

Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification
Published: September 14th 2021 | Updated:
Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics
Published: March 17th 2021 | Updated:

Trending on CancerNetwork

What is the Impact of the SHARON Trial on Pancreatic Cancer Research?

Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy

Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group

Pelareorep Combo Yields Responses in Squamous Cell Anal Carcinoma

ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma

© 2025 MJH Life Sciences^®

All rights reserved.